Final Conference

Overview of the Final Conference

Brussels, February 9th 2009
(In partnership with biotechnology associations from the Member States, Inserm and EuropaBio.)

Report :

Panel discussion I : Clinical Trials Frameworks, Guidelines, Issues and Recommendations

• Frameworks and Guidelines - Detlef Niese, Novartis, EuropaBio
>   Clinical Trials : Frameworks and Guidelines - Detlef Niese, Novartis, EuropaBio

• Issues and Recommendations - Anne Dupraz Poiseau, Voisin Consulting, France Biotech
>    Clinical Trials : Issues and Recommendations - Anne Dupraz Poiseau, Voisin Consulting, France Biotech

Panel discussion II: Gene and Cell Therapy Frameworks, Guidelines, Issues and Recommendations

• European Frameworks and Guidelines – Maurizio Salvi, European Commission
>   Gene and Cell Therapy : European Frameworks and Guidelines – Maurizio Salvi, European Commission

• Issues and Recommendations – David Sourdive, Cellectis, France Biotech
>    Gene and Cell Therapy : Issues and Recommendations – David Sourdive, Cellectis, France Biotech

Panel discussion III: Biobanks Frameworks, Guidelines, Issues and Recommendations

• Framework and Guidelines – Emmanuelle Rial-Sebbag, INSERM U558
>    Biobanks : Framework and Guidelines – Emmanuelle Rial-Sebbag, INSERM U558

• Issues and Recommendations – Karin Aase, SwedenBIO
>    Biobanks : Issues and Recommendations – Karin Aase, SwedenBIO

Panel discussion IV: Genetic testing Frameworks, Guidelines, Issues and Recommendations

• Frameworks and Guidelines – Anne Cambon-Thomsen, INSERM U558
>   Genetic testing : Frameworks and Guidelines – Anne Cambon-Thomsen, INSERM U558

• Issues and Recommendations – Eric Tambuyzer, Genzyme, EuropaBio
>   Genetic testing : Issues and Recommendations – Eric Tambuyzer, Genzyme, EuropaBio

CORE ETHICAL VALUES presented by Eric Tambuyzer - EuropaBio
>    Core Ethical Values : Eric Tambuyzer - EuropaBio

This entry was posted on Lundi, juillet 20th, 2009 at 17 h 47 min and is filed under Final Conference. You can follow any responses to this entry through the RSS 2.0 feed. Responses are currently closed, but you can trackback from your own site.

Comments are closed.